Myovant Sciences Ltd.
NYSE: MYOV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David C. Marek
- Employees
- 579
- Headquarters
- London, United Kingdom
- IPO year
- 2016
- Market cap
- $2.6B
- Website
- https://myovant.com
Loading MYOV…
Loading profile data…Frequently asked questions about MYOV
What does Myovant Sciences Ltd. (MYOV) do?
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menst...
Where does MYOV trade?
Myovant Sciences Ltd. (MYOV) trades on the New York Stock Exchange.
What sector is MYOV in?
Myovant Sciences Ltd. (MYOV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Myovant Sciences Ltd.?
David C. Marek is the chief executive officer of Myovant Sciences Ltd. (MYOV).
Where is Myovant Sciences Ltd. headquartered?
Myovant Sciences Ltd. is headquartered in United Kingdom.
Does MYOV pay a dividend?
Myovant Sciences Ltd. (MYOV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MYOV go public?
Myovant Sciences Ltd. (MYOV) completed its initial public offering in 2016.